InterMune Announces Webcast of Corporate Presentation at the UBS Global Life Sciences Conference
Posted on: Wednesday, 21 September 2005, 18:00 CDT
BRISBANE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today that Dan Welch, InterMune's President and CEO, will present a corporate overview at the UBS Global Life Sciences Conference in New York City on Wednesday, September 28, 2005 at 1:30 p.m. (EDT). To access the live audio webcast, log on to the investor relations page of the Company's website at http://www.intermune.com/. The Company recommends logging on 15 minutes early in order to register or download any necessary software.
About InterMune
InterMune is a biopharmaceutical company focused on the research, development and commercialization of innovative therapies in hepatology and pulmonology. In addition to three-times-a-week Infergen(R) (interferon alfacon-1), a currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, InterMune has a broad and deep late-stage product portfolio addressing HCV infections, particularly nonresponders, or those patients who do not respond to first-line therapy, and idiopathic pulmonary fibrosis (IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen(R) plus ribavirin, and a Phase IIb trial of daily Infergen(R) plus Actimmune(R) (interferon gamma-1b) with and without ribavirin for the treatment of HCV patients who do not respond to first-line therapy. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. The pulmonology portfolio includes pirfenidone and Actimmune(R). Pirfenidone is being developed for the treatment of IPF. Actimmune(R) is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF. For additional information about InterMune and its development pipeline, please visit http://www.intermune.com/.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to anticipated future financial results and product development. All forward- looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's quarterly report on Form 10-Q filed with the SEC on August 9, 2005 (the "Form 10-Q") and other periodic reports filed with the SEC.
InterMune, Inc.
CONTACT: Investors: Judy Hayes of InterMune, Inc., +1-415-466-2242 orir@intermune.com; or Media: Pam Lord of Atkins + Associates, +1-858-527-3494or plord@irpr.com, for InterMune, Inc.
Web site: http://www.intermune.com/
Source: PRNewswire-FirstCall
Related Articles
- Lockheed Martin SBIRS Team Advancing to Follow-on Production Phase
- FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
- Back on Job, Snow Looks Forward to Busy Schedule
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- Ebert Looks Forward to Return to Work
- Rice Looking Forward to Guantanamo Closure
- We Should All Look Forward to a Productive New School Year
- New champion Taylor looking forward to rematch
- Aniston Looks Forward Past 'Friends'
- UK Astronomers Look Forward to Looking Back
 |
 |
User Comments (0)
RSS Feeds